Jefferies Keeps AbbVie (ABBV) As Buy; Has Price Target Of $150.0; Freightcar America (RAIL) Shorts Increased By 16.11%

January 27, 2018 - By rebbecca

Freightcar America Incorporated (NASDAQ:RAIL) had an increase of 16.11% in short interest. RAIL’s SI was 287,500 shares in January as released by FINRA. Its up 16.11% from 247,600 shares previously. With 88,800 avg volume, 3 days are for Freightcar America Incorporated (NASDAQ:RAIL)’s short sellers to cover RAIL’s short positions. The SI to Freightcar America Incorporated’s float is 2.37%. The stock increased 0.12% or $0.02 during the last trading session, reaching $16.18. About 66,429 shares traded. FreightCar America, Inc. (NASDAQ:RAIL) has risen 17.23% since January 27, 2017 and is uptrending. It has outperformed by 0.53% the S&P500.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc has $130.0 highest and $6 lowest target. $83.78’s average target is -32.00% below currents $123.21 stock price. Abbvie Inc had 71 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by SunTrust with “Buy” on Monday, October 16. The firm has “Hold” rating given on Friday, July 28 by Cowen & Co. The rating was maintained by Jefferies with “Buy” on Tuesday, January 16. As per Monday, December 7, the company rating was upgraded by Jefferies. The firm has “Overweight” rating given on Monday, November 2 by Morgan Stanley. SunTrust maintained the shares of ABBV in report on Sunday, October 29 with “Buy” rating. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Friday, September 15 by Jefferies. The stock of AbbVie Inc. (NYSE:ABBV) earned “Outperform” rating by Leerink Swann on Monday, October 2. The stock of AbbVie Inc. (NYSE:ABBV) has “Market Perform” rating given on Monday, June 6 by Cowen & Co. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Thursday, January 4 by Jefferies.

FreightCar America, Inc., through its subsidiaries, designs, makes, and sells railcars for the transportation of bulk commodities and containerized freight products primarily in North America. The company has market cap of $200.56 million. The firm offers a range of freight cars, including open top hoppers, covered hoppers, and gondolas; intermodal flats, such as well cars; and non-intermodal flat cars comprising slab, hot slab, ribbon rail, and bulkhead flats. It currently has negative earnings. It also provides stainless steel and hybrid stainless steel, and aluminum-bodied railcars, such as coal cars; and mill gondolas, coil gondolas, triple hoppers, ore hoppers, ballast hopper cars, aggregate hopper cars, boxcars, woodchip hoppers, aluminum vehicle carriers, and articulated bulk container railcars.

Among 4 analysts covering FreightCar America (NASDAQ:RAIL), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. FreightCar America had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was initiated by Longbow with “Hold” on Wednesday, June 21. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, November 2. The firm earned “Hold” rating on Friday, August 7 by Zacks. On Wednesday, July 13 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The firm has “Hold” rating given on Monday, July 10 by Cowen & Co. The firm has “Hold” rating by Stifel Nicolaus given on Tuesday, November 7. The stock of FreightCar America, Inc. (NASDAQ:RAIL) has “Neutral” rating given on Wednesday, May 4 by Longbow. The rating was maintained by Stifel Nicolaus with “Hold” on Tuesday, September 19. The firm has “Hold” rating given on Thursday, August 3 by Stifel Nicolaus. Cowen & Co maintained FreightCar America, Inc. (NASDAQ:RAIL) rating on Friday, September 8. Cowen & Co has “Hold” rating and $17.0 target.

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.61, from 1.49 in 2017Q2. It worsened, as 7 investors sold FreightCar America, Inc. shares while 35 reduced holdings. 15 funds opened positions while 22 raised stakes. 9.73 million shares or 2.27% more from 9.51 million shares in 2017Q2 were reported. Invesco Ltd owns 64,173 shares. Renaissance Technologies Lc holds 0% in FreightCar America, Inc. (NASDAQ:RAIL) or 41,799 shares. Sterling Capital Mgmt Ltd Company, North Carolina-based fund reported 46,044 shares. Dimensional Fund Advsrs L P has invested 0.01% in FreightCar America, Inc. (NASDAQ:RAIL). Susquehanna Intl Gru Incorporated Ltd Liability Partnership owns 22,135 shares. Tiaa Cref Invest Mngmt Ltd holds 32,499 shares or 0% of its portfolio. Boston Ptnrs reported 0.03% stake. Bancorp Of New York Mellon Corporation has 0% invested in FreightCar America, Inc. (NASDAQ:RAIL). Geode Cap Mngmt Limited holds 102,586 shares or 0% of its portfolio. Deutsche Bank & Trust Ag has 52,781 shares for 0% of their portfolio. Fairfax Financial Limited Can reported 110,000 shares. Systematic Financial Limited Partnership invested in 0.03% or 65,195 shares. American International Grp Incorporated Inc holds 0% in FreightCar America, Inc. (NASDAQ:RAIL) or 8,134 shares. Numeric Ltd Company invested in 0.08% or 536,575 shares. Acadian Asset Mngmt Ltd Liability Corporation holds 132,172 shares or 0.01% of its portfolio.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It is negative, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Meag Munich Ergo Kapitalanlagegesellschaft Mbh accumulated 139,855 shares or 0.51% of the stock. First Republic Invest has invested 0.78% in AbbVie Inc. (NYSE:ABBV). Moreover, Utah Retirement System has 0.58% invested in AbbVie Inc. (NYSE:ABBV) for 292,405 shares. Jacobus Wealth Mgmt Inc has 59,210 shares for 1.38% of their portfolio. Northwestern Mutual Wealth, a Wisconsin-based fund reported 115,456 shares. Wright Serv Inc, Connecticut-based fund reported 50,745 shares. Willingdon Wealth owns 69,030 shares. State Treasurer State Of Michigan holds 0.49% or 686,503 shares in its portfolio. 5,926 are owned by Palisades Hudson Asset Mngmt Lp. Tradition Cap Management Ltd Limited Liability Company reported 113,916 shares. Ipswich Inv Mngmt owns 0.18% invested in AbbVie Inc. (NYSE:ABBV) for 4,420 shares. 5,266 were reported by American Asset Management. The Manitoba – Canada-based Great West Life Assurance Can has invested 0.31% in AbbVie Inc. (NYSE:ABBV). Capital World Invsts stated it has 0.31% of its portfolio in AbbVie Inc. (NYSE:ABBV). Thompson Siegel Walmsley Limited Co has 58,290 shares for 0.06% of their portfolio.

Since July 31, 2017, it had 0 buys, and 7 insider sales for $45.55 million activity. 300 shares valued at $21,127 were sold by Gosebruch Henry O on Monday, July 31. Shares for $705,655 were sold by SALEKI-GERHARDT AZITA. Shares for $589,512 were sold by Michael Robert A.. The insider Schumacher Laura J sold $14.07 million. Shares for $6.24 million were sold by GONZALEZ RICHARD A on Thursday, August 3. 87,040 shares were sold by RICHMOND TIMOTHY J., worth $8.57M.

The stock increased 13.77% or $14.91 during the last trading session, reaching $123.21. About 19.61M shares traded or 286.79% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 27, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $196.70 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 37.34 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.